Phagocytosis of platelets opsonized with differently glycosylated anti-HLA hIgG1 by monocyte-derived macrophages

References

• Bub CB, Gonçalez AC, Barjas-Castro ML, Castro V. Prospective evaluation of platelet refractoriness in haematological patients in a single Brazilian institution. ISBT Sci Ser. 2021;16(1):1–9.
   Google Scholar
• Hu X, Cai H, Zheng L, Luo Y, Zhou J, Hui Y, Dai Z, Lin H, Li D, Xiao Y, et al. Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia. Cancer Med. 2020;9(14):4941–4948. doi: 10.1002/cam4.3140.
   PubMed Web of Science ®Google Scholar
• Comont T, Tavitian S, Bardiaux L, Fort M, Debiol B, Morère D, Bérard E, Delabesse E, Luquet I, Martinez S, et al. Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. Leuk Res. 2017;61:62–67. doi: 10.1016/j.leukres.2017.08.015.
   PubMed Web of Science ®Google Scholar
• Hess JR, Trachtenberg FL, Assmann SF, Triulzi DJ, Kaufman RM, Strauss RG, Granger S, Slichter SJ. Clinical and laboratory correlates of platelet alloimmunization and refractoriness in the PLADO trial. Vox Sang. 2016;111(3):281–291. doi: 10.1111/vox.12411
   PubMed Web of Science ®Google Scholar
• Novotny VM, van Doorn R, Witvliet MD, Claas FH, Brand A. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood. 1995;85(7):1736–1741.
   PubMed Web of Science ®Google Scholar
• Jia Y, Li W, Liu N, Zhang K, Gong Z, Li D, Wang L, Wang D, Jing Y, Wang J, et al. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients. Transfus Med. 2014;24(6):406–410. doi: 10.1111/tme.12157.
   PubMed Web of Science ®Google Scholar
• Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens. 2012;79(4):237–245.
   PubMedGoogle Scholar
• Saris A, Pavenski K. Human leukocyte antigen alloimmunization and alloimmune platelet refractoriness. Transfus Med Rev. 2020;34(4):250–257.
   PubMed Web of Science ®Google Scholar
• Vassallo RR. Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients. Immunohematology. 2009;25(3):119–124
   PubMedGoogle Scholar
• Badlou BA, Ya PW, Smid WM, Akkerman JWN. Platelet binding and phagocytosis by macrophages. Transfusion. 2006;46(8):1432–1443.
   PubMed Web of Science ®Google Scholar
• Grozovsky R, Hoffmeister KM, Falet H. Novel clearance mechanisms of platelets. Curr Opin Hematol. 2010;17(6):585–589.
   PubMed Web of Science ®Google Scholar
• Rijkers M, Saris A, Heidt S, Mulder A, Porcelijn L, Claas FH, Bierings R, Leebeek FW, Jansen AG, Vidarsson G, et al. A subset of anti-HLA antibodies induces Fcγriia-dependent platelet activation. Haematologica. 2018;103(10):1741–1752.
   PubMed Web of Science ®Google Scholar
• Aslam R, Kapur R, Segel GB, Guo L, Zufferey A, Ni H, Semple JW. The spleen dictates platelet destruction, anti-platelet antibody production, and lymphocyte distribution patterns in a murine model of immune thrombocytopenia. Exp Hematol. 2016;44(10):924–930.e1. doi: 10.1016/j.exphem.2016.07.004.
   PubMed Web of Science ®Google Scholar
• Audia S, Santegoets K, Laarhoven AG, Vidarsson G, Facy O, Ortega-Deballon P, Samson M, Janikashvili N, Saas P, Bonnotte B, et al. Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia. Clin Exp Immunol. 2017;188(2):275–282. doi: 10.1111/cei.12935.
   PubMed Web of Science ®Google Scholar
• Meinke S, Karlström C, Höglund P. Complement as an immune barrier in platelet transfusion refractoriness. Transfus Med Rev. 2019;33(4):231–235.
   PubMed Web of Science ®Google Scholar
• Rijkers M, Schmidt D, Lu N, Kramer CS, Heidt S, Mulder A, Porcelijn L, Claas FH, Leebeek FW, Jansen AG, et al. Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets. Haematologica. 2019;104(2):403–416.
   PubMed Web of Science ®Google Scholar
• Rebulla P. Refractoriness to platelet transfusion. Curr Opin Hematol. 2002;9(6):516–520.
   PubMed Web of Science ®Google Scholar
• Group T to RA to PS. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med. 1997;337(26):1861–1870.
   PubMed Web of Science ®Google Scholar
• Wuhrer M, Porcelijn L, Kapur R, Koeleman CAM, Deelder AM, de Haas M, Vidarsson G. Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J Proteome Res. 2009;8(2):450–456. doi: 10.1021/pr800651j.
   PubMed Web of Science ®Google Scholar
• Kapur R, Kustiawan I, Vestrheim A, Koeleman CAM, Visser R, Einarsdottir HK, Porcelijn L, Jackson D, Kumpel B, Deelder AM, et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood. 2014;123(4):471–480. doi: 10.1182/blood-2013-09-527978.
   PubMed Web of Science ®Google Scholar
• Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, Lissenberg-Thunnissen SN, Visser R, Brouwer M, Mok JY, et al. Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities. Front Immunol. 2017;8(AUG): doi:10.3389/fimmu.2017.00877.
   Web of Science ®Google Scholar
• Larsen MD, de Graaf EL, Sonneveld ME, Plomp HR, Nouta J, Hoepel W, Chen H-J, Linty F, Visser R, Brinkhaus M, et al. Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity. Science. 2021;371(6532): doi: 10.1126/science.abc8378.
   PubMed Web of Science ®Google Scholar
• van Osch TLJ, Nouta J, Derksen NIL, van Mierlo G, van der Schoot CE, Wuhrer M, Rispens T, Vidarsson G. Fc Galactosylation promotes hexamerization of human IgG1, leading to enhanced classical complement activation. J Immunol. 2021;207(6):1545–1554. doi: 10.4049/jimmunol.2100399.
   PubMed Web of Science ®Google Scholar
• Peschke B, Keller CW, Weber P, Quast I, Lünemann JD. Fc-Galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front Immunol. 2017;8(JUN):646.
   PubMed Web of Science ®Google Scholar
• Sonneveld ME, Natunen S, Sainio S, Koeleman CAM, Holst S, Dekkers G, Koelewijn J, Partanen J, van der Schoot CE, Wuhrer M, et al. Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia. Br J Haematol. 2016;174(2):310–320. doi: 10.1111/bjh.14053.
   PubMed Web of Science ®Google Scholar
• Wang TT, Maamary J, Tan GS, Bournazos S, Davis C, Krammer F, Schlesinger S, Palese P, Ahmed R, Ravetch J. Anti-HA Glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell. 2015;162(1):160–169. doi: 10.1016/j.cell.2015.06.026.
   PubMed Web of Science ®Google Scholar
• Selman MHJ, De Jong SE, Soonawala D, Kroon FP, Adegnika AA, Deelder AM, Hokke CH, Yazdanbakhsh M, Wuhrer M. Changes in antigen-specific IgG1 Fc N-glycosylation upon influenza and tetanus vaccination. Mol Cell Proteomics. 2012;11(4):1–10. doi: 10.1074/mcp.M111.014563
   Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5(OCT):1–17.
   PubMed Web of Science ®Google Scholar
• Temming AR, de Taeye SW, de Graaf EL, de Neef LA, Dekkers G, Bruggeman CW, Koers J, Ligthart P, Nagelkerke SQ, Zimring JC, et al. Functional attributes of antibodies, effector cells, and target cells affecting NK cell–mediated antibody-dependent cellular cytotoxicity. J Immunol. 2019;203(12):3126–3135. doi: 10.4049/jimmunol.1900985.
   PubMed Web of Science ®Google Scholar
• Wei B, Gao X, Cadang L, Izadi S, Liu P, Zhang HM, Hecht E, Shim J, Magill G, Pabon JR, et al. Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation. MAbs. 2021;13(1):1–10.
   Web of Science ®Google Scholar
• Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang L-X, Münz C, Nimmerjahn F, Dalakas MC, Lünemann JD. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest. 2015;125(11):4160–4170. doi: 10.1172/JCI82695.
   PubMed Web of Science ®Google Scholar
• Wada R, Matsui M, Kawasaki N. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. MAbs. 2019;11(2):350–372.
   PubMed Web of Science ®Google Scholar
• van Osch TLJ, Pongracz T, Geerdes DM, Mok JY, van Esch WJE, Voorberg J, Kapur R, Porcelijn L, Kerkhoffs JLH, van der Meer PF, et al. Altered Fc glycosylation of anti-HLA alloantibodies in haemato-oncological patients receiving platelet transfusions. J Thromb Haemost.2022. doi: 10.1111/jth.15898.
   PubMed Web of Science ®Google Scholar
• Crow AR, Lazarus AH. Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003;25 Suppl(1):S14–8.
   Web of Science ®Google Scholar
• Meinke S, Sandgren P, Mörtberg A, Karlström C, Kadri N, Wikman A, Höglund P. Platelets made HLA deficient by acid treatment aggregate normally and escape destruction by complement and phagocytes in the presence of HLA antibodies. Transfusion. 2016;56(2):370–382. doi: 10.1111/trf.13350.
   PubMed Web of Science ®Google Scholar
• Uribe-Querol E, Rosales C. Phagocytosis: our current understanding of a universal biological process. Front Immunol. 2020;11(June):1–13.
   PubMed Web of Science ®Google Scholar
• Dustin ML. Complement receptors in myeloid cell adhesion and phagocytosis. Microbiol Spectr. 2016;4(6). doi: 10.1128/microbiolspec.MCHD-0034–2016.
   PubMed Web of Science ®Google Scholar
• Norris PAA, Segel GB, Burack WR, Sachs UJ, Lissenberg-Thunnissen SN, Vidarsson G, Bayat B, Cserti-Gazdewich CM, Callum J, Lin Y, et al. FcγRI and FcγRIII on splenic macrophages mediate phagocytosis of anti-glycoprotein IIb/IIIa autoantibody-opsonized platelets in immune thrombocytopenia. Haematologica. 2021;106(1):250–254. doi: 10.3324/haematol.2020.248385.
   PubMed Web of Science ®Google Scholar
• Ho MK, Springer TA. Mac-1 antigen: quantitative expression in macrophage populations and tissues, and immunofluorescent localization in spleen. J Immunol. 1982;128(5):2281 LP–2286.
   Web of Science ®Google Scholar
• Schittenhelm L, Hilkens CM, Morrison VL. β(2) Integrins as regulators of dendritic cell, monocyte, and macrophage function. Front Immunol. 2017;8:1866.
   PubMed Web of Science ®Google Scholar
• Prieto J, Eklund A, Patarroyo M. Regulated expression of integrins and other adhesion molecules during differentiation of monocytes into macrophages. Cell Immunol. 1994;156(1):191–211.
   PubMed Web of Science ®Google Scholar
• Vo P, Purev E, West KA, McDuffee E, Worthy T, Cook L, Hawks G, Wells B, Shalabi R, Flegel WA, et al. A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients. Br J Haematol. 2020;189(3):551–558. doi: 10.1111/bjh.16385.
   PubMed Web of Science ®Google Scholar
• Jackman RP, Lee JH, Pei R, Bolgiano D, Lebedeva M, Slichter SJ, Norris PJ. C1q-Binding anti-HLA antibodies do not predict platelet transfusion failure in trial to reduce alloimmunization to platelets study participants. Transfusion. 2016;56(6):1442–1450. doi: 10.1111/trf.13598.
   PubMed Web of Science ®Google Scholar
• Saris A, Peyron I, van der Meer PF, Stuge TB, Zwaginga JJ, van Ham SM, ten Brinke A. Storage-Induced platelet apoptosis is a potential risk factor for alloimmunization upon platelet transfusion. Front Immunol. 2018;9(JUN):1–10. doi: 10.3389/fimmu.2018.01251.
   PubMed Web of Science ®Google Scholar
• Peerschke EIB, Andemariam B, Yin W, Bussel JB. Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol. 2010;148(4):638–645.
   PubMed Web of Science ®Google Scholar
• Dekkers G, Plomp R, Koeleman CAM, Visser R, von Horsten HH, Sandig V, Rispens T, Wuhrer M, Vidarsson G. Multi-Level glyco-engineering techniques to generate IgG with defined Fc-glycans. Sci Rep. 2016;6:1–12. doi: 10.1038/srep36964.
   PubMed Web of Science ®Google Scholar
• van Osch TLJ, Oosterhoff JJ, Bentlage AEH, Nouta J, Koeleman CAM, Geerdes DM, Mok JY, Heidt S, Mulder A, Van Esch WJE, et al. Fc galactosylation of anti-platelet hIgg1 alloantibodies enhance complement activation on platelets. Haematologica. 2022. doi: 10.3324/haematol.2021.280493.
   PubMed Web of Science ®Google Scholar
• Mulder A, Kardol MJ, Arn JS, Eijsink C, Franke MEI, Schreuder GMT, Haasnoot GW, Doxiadis IIN, Sachs DH, Smith DM, et al. Human monoclonal HLA antibodies reveal interspecies crossreactive swine MHC class I epitopes relevant for xenotransplantation. Mol Immunol. 2010;47(4):809–815. doi: 10.1016/j.molimm.2009.10.004
   PubMed Web of Science ®Google Scholar
• Mulder A, Eijsink C, Kester MGD, Franke ME, Kardol MJ, Heemskerk MH, van Kooten C, Verreck FA, Drijfhout JW, Koning F, et al. Impact of peptides on the recognition of HLA class I molecules by human HLA antibodies. J Immunol. 2005;175(9):5950–5957.
   PubMed Web of Science ®Google Scholar
• Daga S, Moyse H, Briggs D, Lowe D, Evans N, Jones J, Buchli R, McMurtrey C, Mulder A, Hildebrand W, et al. Human immunology direct quantitative measurement of the kinetics of HLA-specific antibody interactions with isolated HLA proteins. Hum Immunol. 2018;79(2):122–128.
   PubMed Web of Science ®Google Scholar
• Duquesnoy RJ, Marrari M, Jelenik L, Zeevi A, Claas FHJ, Mulder A. Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays. Hum Immunol. 2013;74(10):1271–1279. doi: 10.1016/j.humimm.2013.05.016.
   PubMed Web of Science ®Google Scholar
• Congy-Jolivet N, Drocourt D, Portet S, Tiraby G, Blancher A. Production and characterization of chimeric anti-HLA monoclonal antibodies targeting public epitopes as tools for standardizations of the anti-HLA antibody detection. J Immunol Methods. 2013;390(1–2):41–51.
   PubMed Web of Science ®Google Scholar
• Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes J-M, Zhang Y, Lin YL, Chung S, Dennis MS, Zuchero YJY, et al. Effector-Attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J Biol Chem. 2017;292(9):3900–3908. doi: 10.1074/jbc.M116.767749.
   PubMed Web of Science ®Google Scholar
• Falck D, Jansen BC, de Haan N, Wuhrer M. High-Throughput analysis of IgG Fc glycopeptides by LC-MS. Methods Mol Biol. 2017;1503:31–47.
   PubMedGoogle Scholar
• Temming AR, Bentlage AEH, de Taeye SW, Bosman GP, Lissenberg-Thunnissen SN, Derksen NIL, Brasser G, Mok JY, van Esch WJE, Howie HL, et al. Cross-Reactivity of mouse IgG subclasses to human Fc gamma receptors: antibody deglycosylation only eliminates IgG2b binding. Mol Immunol. 2020;127(March):79–86. doi: 10.1016/j.molimm.2020.08.015.
   PubMed Web of Science ®Google Scholar
• Dekkers G, Bentlage AEH, Stegmann TC, Howie HL, Lissenberg-Thunnissen S, Zimring J, Rispens T, Vidarsson G. Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs. 2017;9(5):767–773. doi: 10.1080/19420862.2017.1323159.
   PubMed Web of Science ®Google Scholar
• ten Brinke A, Karsten ML, Dieker MC, Zwaginga JJ, van Ham SM. The clinical grade maturation cocktail monophosphoryl lipid a plus IFNγ generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization. Vaccine. 2007;25(41):7145–7152.
   PubMed Web of Science ®Google Scholar
• Saris A, Tomson B, Brand A, Mulder A, Claas FH, Lorinser J, Scharenberg J, van Ham SM, ten Brinke A, Zwaginga JJ, et al. Platelets from donors with consistently low HLA-B8, -B12, or -B35 expression do not undergo antibody-mediated internalization. Blood. 2018;131(1):144–152. doi: 10.1182/blood-2017-07-799270.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, van de Winkel JG. Fc receptor and complement receptor-mediated phagocytosis in host defence. Curr Opin Infect Dis. 1998;11(3):271–278.
   PubMed Web of Science ®Google Scholar
• Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, Koeleman CAM, Wuhrer M, van den Berg TK, Rispens T, et al. Enhanced effector functions due to antibody defucosylation depend on the effector cell Fcγ receptor profile. J Immunol. 2017;199(1):204–211. doi: 10.4049/jimmunol.1700116.
   PubMed Web of Science ®Google Scholar
• Nagelkerke SQ, Dekkers G, Kustiawan I, van de Bovenkamp FS, Geissler J, Plomp R, Wuhrer M, Vidarsson G, Rispens T, van den Berg TK, et al. Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages. 2014;124(25):3709–3718. doi: 10.1182/blood-2014-05-576835.
   Google Scholar
• Walbaum S, Ambrosy B, Schütz P, Bachg AC, Horsthemke M, Leusen JHW, Mócsai A, Hanley PJ. Complement receptor 3 mediates both sinking phagocytosis and phagocytic cup formation via distinct mechanisms. J Biol Chem. 2021;296:100256. doi: 10.1016/j.jbc.2021.100256.
   PubMed Web of Science ®Google Scholar